We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Statins Help Lower Risk of Atherosclerosis by Reducing the Size of Arterial Plaques

By LabMedica International staff writers
Posted on 26 Dec 2011
Statins, a class of drugs that help reduce risk of atherosclerosis by lowering levels of low-density lipoproteins (LDL), also decrease the size of arterial plaques by stimulating macrophage emigration.

Investigators at New York University (NY, USA) worked with a novel mouse-transplant model of atherosclerosis regression in which aortic segments from diseased donors were placed into recipients with normal cholesterol levels. More...
With this model they had previously shown that the induction of a chemokine receptor CCR7(C-C chemokine receptor type 7)-dependent emigration process triggered the rapid loss of CD68+ cells (mainly macrophages) from arterial plaques.

In the current study, the investigators examined the effect of statins on macrophage emigration from plaques. They reported in the December 6, 2011, online edition the journal PLoS One that when mice that had been genetically engineered to lack the gene for apolipoprotein E were fed a western diet-fed while being treated with either atorvastatin or rosuvastatin they experienced a substantial reduction in the CD68+ cell content in the plaques despite continued hyperlipidemia. There was a significant increase in CCR7 mRNA in CD68+ cells from both atorvastatin and rosuvastatin treated mice associated with emigration of CD68+ cells from plaques. Mice that lacked both the gene for apolipoprotein E and the gene for CCR7 failed to display a reduction in CD68+ cell content upon statin treatment.

The results of this study indicate that statins, in addition to their traditionally considered effects on atherosclerosis by retarding plaque progression through lowering LDL-cholesterol, may also have additional clinical benefits by accelerating plaque regression through enhancing CCR7 expression and emigration of CD68+ macrophages. These beneficial effects would have been missed if changes in plaque size had been the sole criterion of success.

“Our experimental findings indicate that statins, in addition to lowering LDL cholesterol, have clinical benefits of accelerating plaque regression by a newly discovered mechanism,”said senior author Dr, Michael Garabedian, professor of microbiology and urology at New York University. “It is possible that these drugs could possibly be more beneficial to a wider population of patients potentially reducing the overall lifetime burden of plaque and the prevention of atherosclerosis.”

Related Links:

New York University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
Prefilled Tubes
Prefilled 5.0ml Tubes
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers identified 157 metabolites linked to BBB damage, including 25 that appeared in at least two independent studies (Image Credit: Adobe Stock)

Blood Metabolite Patterns May Enable Early Detection of Blood-Brain Barrier Injury

Early injury to the blood-brain barrier (BBB) can precede many neurological disorders but remains difficult to detect noninvasively. Laboratory markers that identify barrier dysfunction before symptoms... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.